Pancreatic Metastatic Cancer, Toxicity
Conditions
Keywords
Pancreatic metastatic cancer, FOLFIRINOX, toxicity, efficacy
Brief summary
Metastatic pancreatic carcinomas represent the 5th cause of cancer death in France (#8000 per year). The median age at diagnosis is 69 and 74 in male and female respectively. When the 5-Fluorouracile has been used as a single agent with a limited efficacy during more than 20 years, the onset of gemcitabine in 1995 has led to a moderate increase of median survival (from 4.41 to 5.65 months) and overall survival at 1 year (2 versus 18%). Recently, in a phase II followed by a phase-III study, a French collaborative group has demonstrated the benefit of "FOLFIRINOX " regimen versus gemcitabine alone, in terms of median survival (11.1 versus 6.8 months), progression-free survival (6.4 versus 3.3 months) and response rate (31.6 versus 9.4%). Although more hematologic (neutropenia) and GI toxicities were observed, FOLFIRINOX was acceptable as a new standard regimen for the majority of patients under the age of 70 with a good Performans Status. To reduce the toxicity of FOLFIRINOX in elderly patients (\> 70 yo), pharmacogenetic monitoring of 5-FU and Irinotecan key metabolism enzymes (DPD and UGTA1) may be easily performed. The methodology of the study is to use the Bryant & Day statistical method, allowing to consider simultaneously as principal objective, the response rate (efficacy) and the tolerance (preservation of autonomy daily living, Katz index): this design is particularly fitting in a study for elderly patients who represent half of the pancreatic carcinoma population.
Detailed description
METHODOLOGY : Phase II study, opened, multicentric MAIN OBJECTIVE : The main objective is the simultaneous evaluation of the objective rate of answer and toxicity of her(it) of the protocol FOLFIRINOX administered to doses adapted at patients of 70 and more years old. SECONDARY OBJECTIVE : * Efficiency evaluation; * Tolerance evaluation; * Quality of Life (QoL) and clinical profit. STATISTICAL ANALYSIS: An analysis in two stages is planned, according to the method of Bryant and Day with a risk ß 5 % to reject wrongly an effective treatment and of acceptable toxicity and a risk a=10 % to accept wrongly a not rather effective or too toxic treatment. The study will be considered as successful if: * we obtain at least 11 tumoral answers and * maxi 30 patients on 72 are in loss of autonomy (decrease of their ADL). * All the patients who will have received at least an injection will be eligible for the evaluation of the toxicity * The evaluation of the efficiency will be made after 3 cures at least unless early termination where the scanner will be anticipated. * All the toxicity will be increased according to criteria of toxicity NCI-CTC v4.0. * The evaluation of the tumoral answer (CR, PR and SD) will be made according to the criteria RECIST-v1.1.
Interventions
DRUGOxaliplatine
Oxaliplatine : 85mg/m², 2-hours IV infusion (D1),
DRUGFolinic acid
Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
DRUGIrinotecan
Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts * Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max. * Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance.
DRUG5-FU
5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion: * If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one * If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course.
Sponsors
Institut Cancerologie de l'Ouest
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven ductal pancreatic carcinoma * Metastatic disease * First-line treatment : No previous chemotherapy in metastatic stage but adjuvant treatment before relapse (secondary metastatic) is permitted, provide it has been administered more than 6 months before) * Age of 70 yo or above * Normal DPD enzyme level or partial defect (excluding total defect) * Adequate bone marrow reserve: as indicated by : neutrophils \>1500/mm3, platelets \>100,000/ mm3, Hb \>10.0g/dL. * Adequate Renal function as indicated by: MDRD creatinine clearance \> 50ml/min. * Adequate hepatic function as indicated by: serum bilirubin \< 1.5 times the upper limit of normal, AST and ALT \< 2.5 times the upper limit of normal, or \< 5 times the upper limit of normal if liver metastases are present. * Written informed consent must be obtained prior to protocol-specific procedures are being performed * Patient is affiliated to a social security category
Exclusion criteria
* Other than ductal pancreatic carcinoma: namely endocrin tumors, acinar cells carcinoma, cystadenocarcinoma or adenocarcinoma of the ampulla of vater * Non-metastatic but locally advanced pancreatic adenocarcinoma * Complete DPD deficiency * History of Cardiac failure or symptomatic coronary artery disease * Autonomy Daily Living score by Katz \<4 * Prior treatment with FOLFIRINOX (adjuvant) * Major comorbidity likely to be an obstacle to treatment * Active or uncontrolled infection such as HIV or chronic B or C hepatitis * Uncontrolled diabetes mellitus * Prior peripheral neuropathy, grade \> 2 * Inflammatory bowel disease localized on the colon or rectum; bowel obstruction or severe uncontrolled diarrhea * Previous or concomitant malignancies other than effectively treated carcinoma in situ of the cervix or non-melanoma skin cancer * Hereditary fructose intolerance * Persons deprived of liberty or under guardianship * Any social, geographical or psychological condition which would compromise the ability to fully comply with the trial procedures and treatments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite Safety and Early Efficacy Assessment in the First 34 Patients | From treatment initiation through Week 12 | This outcome is a composite assessment combining safety and early efficacy signals in the first 34 enrolled patients. Safety is measured by the occurrence of grade ≥3 toxicities (NCI-CTCAE v4.0). Early efficacy is assessed by the presence or absence of tumor response according to predefined stopping rules. Both components contribute jointly to the decision-making criteria for continuation of the study. This description corresponds specifically to the data reported in the Results section. |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORSandrine HIRET, MD
Institut de Cancérologie de l'Ouest (ICO) - Nantes, France
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 69 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Region of Enrollment France | 69 participants |
| Sex: Female, Male Female | 35 Participants |
| Sex: Female, Male Male | 34 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 63 / 69 |
| other Total, other adverse events | 69 / 69 |
| serious Total, serious adverse events | 48 / 69 |
Outcome results
None listed